Alexander Dömling studied chemistry & biology at the Technical University Munich. After performing his PhD under the supervision of Ivar Ugi he spent his postdoctoral year at the Scripps Research Institute in the group of Barry Sharpless. He is founder of several biotech companies, including Morphochem and R&D Biopharmaceuticals. In 2004 we performed his habilitation in chemistry at the Technical University of Munich. Since 2006 he is professor at the University of Pittsburgh in the Department of Pharmacy and Chemistry and most recently Chair of Drug Design at the University of Groningen. He is author of more than 100 papers, reviews and book contributions.
ICON is a global provider of outsourced drug development services to biopharma, medical device , government , biosimilar and generic organisations.
We offer a full range of clinical , consulting and commercial services that range from trial design to full study execution, and from clinical to post-market commercialisation .
Our services are supported by in-depth therapeutic and regulatory expertise and market-leading technology and analytics. We are the only full service CRO that offers the knowledge, software and systems for adaptive trials .